According to the research report titled ‘Breast Cancer Therapeutics Market Size By Product, By Distribution Channel, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2019 – 2025’, available with Market Study Report, the worldwide breast cancer therapeutics market is expected to surpass USD 30,637.7 million by the year 2025.
 

Rising adoption of western lifestyle has enhanced the pervasiveness of breast cancer, in turn driving the growth of breast cancer therapeutics industry. Availability of favorable reimbursement policies is further aiding the market expansion. However, high costs associated with breast cancer therapeutics may hinder the overall market growth.
 

Based on the product landscape, targeted drug therapy segment was worth USD 11,559.6 million in 2018 and will showcase similar growth pattern over the ensuing years. Rising R&D activities have facilitated the development of efficient targeted breast cancer therapy.
 

Request sample copy of this Report: https://www.marketstudyreport.com/request-a-sample/616481/
 

Citing the distribution channel, breast cancer therapeutics market from retail pharmacies segment is presumed to expand with a CAGR of 9.7% during 2019-2025. Shifting preference towards retail pharmacies owing to reimbursement option and extended use of oral formulations are fueling the segmental growth.
 

Considering the geographical landscape, Germany breast cancer therapeutics industry was worth USD 1,318.2 million in 2018 and is poised to acquire admirable returns by the year 2025. Escalating healthcare expenditure and rising prevalence of breast cancer are promoting the business scenario in Germany.
 

Alternatively, breast cancer therapeutics industry in China is anticipated to witness a growth rate of 13.7% between 2019 and 2025. High occurrence of breast cancer and economic improvements will propel China market growth.
 

The established companies in breast cancer therapeutics industry are Celgene, Sanofi, Eli Lilly, Eisai, Novartis, Pfizer, Roche Diagnostics and AstraZeneca.